InVivo Therapeutics has recruited seventeenth patient in the study of its neuro-spinal scaffold.
The new patient was enrolled at the Thomas Jefferson University Hospital in Philadelphia, Pennsylvania.
The Neuro-Spinal Scaffold, which is an investigational device that secured a humanitarian use device (HUD) designation, is being assessed in the INSPIRE study to treat patients with acute, complete (AIS A), thoracic traumatic spinal cord injury.
In addition, the pilot study is being carries out to evaluate the device in the treatment of acute and complete (AIS A), cervical (C5-T1) traumatic spinal cord injury.
The implantation of the biodegradable Neuro-Spinal Scaffold within the decompressed and debrided injury epicenter will help in appositional healing following acute spinal cord injury.
It will enable to reduce post-traumatic cavity formation, sparing white matter, in addition to allowing neural repair within and around the healed wound epicenter.
The study principal investigator Dr James Harrop said: “The surgery and implantation went smoothly and the patient is recovering well. We are excited to be part of The INSPIRE Study and we look forward to following and communicating the patient’s progress.”
InVivo Therapeutics CEO and chairman Mark Perrin said: “We now have 17 patients enrolled and in follow up, and with this patient marking the second enrollment in the last week, we remain enthusiastic about completing INSPIRE enrollment during the third quarter of this year.”
Image: The Neuro-Spinal Scaffold is being evaluated in the INSPIRE study to treat patients with acute and complete, thoracic traumatic spinal cord injury. Photo: courtesy of cooldesign / FreeDigitalPhotos.net.